Antiemesis Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lowerlevel evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lowerlevel evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewChemotherapy-induced vomiting (emesis) and nausea can significantly affect a patient's quality of life, leading to poor compliance with further chemotherapy treatment. Nausea and vomiting can also result in metabolic imbalances, degeneration of self-care and functional ability, nutrient depletion, anorexia, decline of performance and mental status, wound dehiscence, esophageal tears, and withdrawal from potentially useful or curative anticancer treatment.1–4The incidence and severity of nausea and/or vomiting in patients undergoing chemotherapy are affected by numerous factors, including 1) the specific chemotherapeutic agents used, 2) dosage of the agents, 3) schedule and route of administration of the agents, and 4) individual patient variability (e.g., age, sex, prior chemotherapy, history of alcohol use). Approximately 70% to 80% of all patients undergoing chemotherapy experience nausea and/or vomiting,5,6 whereas 10% to 44% experience anticipatory nausea and/or vomiting;7–10 patients often experience more...
  • 1

    LaszloJ. Emesis as limiting toxicity in cancer chemotherapy. In: LaszloJ ed. Antiemetics and Cancer Chemotherapy. Baltimore: Williams & Wilkins; 1983:15.

    • Search Google Scholar
    • Export Citation
  • 2

    IngleRJBurishTGWallstonKA. Conditionability of cancer chemotherapy patients. Oncol Nurs Forum1984;11:97102.

  • 3

    MitchellEP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol1992;19:566579.

  • 4

    RichardsonJLMarksGLevineA. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol1988;5:17461752.

    • Search Google Scholar
    • Export Citation
  • 5

    MorranCSmithDCAndersonDA. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. Br Med J1979;1:13231324.

    • Search Google Scholar
    • Export Citation
  • 6

    JennsK. Importance of nausea. Cancer Nurs1994;17:488493.

  • 7

    NesseRMCarliTCurtisGC. Pretreatment nausea in cancer chemotherapy: a conditioned response?Psychosom Med1980;42:3336.

  • 8

    WilcoxPMFettingJHNettesheimKM. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep1982;66:16011604.

    • Search Google Scholar
    • Export Citation
  • 9

    CareyMPBurishTG. Anxiety as a predictor of behavioral therapy outcome for cancer chemotherapy patients. J Consult Clin Psychol1985;53:860865.

    • Search Google Scholar
    • Export Citation
  • 10

    MorrowGRLindkeJBlackPM. Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manag1991;6:215223.

    • Search Google Scholar
    • Export Citation
  • 11

    HickokJTRoscoeJAMorrowGR. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol2005;6:765772.

    • Search Google Scholar
    • Export Citation
  • 12

    CraigJBPowellBL. The management of nausea and vomiting in clinical oncology. Am J Med Sci1987;293:3444.

  • 13

    BorisonHLWangS. Physiology and pharmacology of vomiting. Pharmacol Rev1953;5:193230.

  • 14

    SiegelLJLongoDL. The control of chemotherapy-induced emesis. Ann Intern Med1981;95:352359.

  • 15

    DoddsLJ. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm1985;10:143166.

  • 16

    KrisMGGrallaRJClarkRA. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol1985;3:13791384.

    • Search Google Scholar
    • Export Citation
  • 17

    RoilaFBoschettiETonatoM. Predictive factors of delayed emesis in cisplatin patients and anti-emetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol1991;14:238242.

    • Search Google Scholar
    • Export Citation
  • 18

    MoherDArthurAZPeterJL. Anticipatory nausea and/or vomiting in chemotherapy patients. Cancer Treat Rev1984;11:257264.

  • 19

    JacobsenPBReddWH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest1988;6:329336.

    • Search Google Scholar
    • Export Citation
  • 20

    MorrowGR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol1984;2:11701176.

    • Search Google Scholar
    • Export Citation
  • 21

    HardingRKYoungRWAnnoGH. Radiotherapy-induced emesis. In: AndrewsPLRSangerGJ eds. Emesis in Anti-Cancer Therapy. London: Chapman & Hall Medical; 1993:163178.

    • Search Google Scholar
    • Export Citation
  • 22

    RoilaFHeskethPJHerrstedtJ. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol2006;17:2028.

    • Search Google Scholar
    • Export Citation
  • 23

    KrisMGHeskethPJSomerfieldMR. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol2006;24:29322947.

    • Search Google Scholar
    • Export Citation
  • 24

    LaszloJ. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev1982;9:39.

  • 25

    StrumSBMcDermedJEPileggiJ. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. Cancer1984;53:14321439.

    • Search Google Scholar
    • Export Citation
  • 26

    LindleyCMBernardSFieldsSM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol1989;7:11421149.

    • Search Google Scholar
    • Export Citation
  • 27

    AaproMS. Methodological issues in anti-emetic studies. Invest New Drugs1993;11:243253.

  • 28

    HeskethPJKrisMGGrunbergSM. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol1997;15:103109.

  • 29

    GrunbergSMOsobaDHeskethPJ. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity–an update. Support Care Cancer2005;13:8084.

    • Search Google Scholar
    • Export Citation
  • 30

    KoellerJMAaproMSGrallaRJ. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer2002;10:519522.

  • 31

    HeskethPJGandaraDR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst1991;83:613620.

  • 32

    AndrewsPLBhandariPDaveyPT. Are all 5-HT3 receptor antagonists the same?Eur J Cancer1992;28A(Suppl 1):S26.

  • 33

    GrunbergSMKoellerJM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother2003;4:22972303.

    • Search Google Scholar
    • Export Citation
  • 34

    GrunbergSMStevensonLLRussellCA. Dose-ranging phase I study of the serotonin antagonist GR 38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol1989;7:11371141.

    • Search Google Scholar
    • Export Citation
  • 35

    ChevallierB. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer1990;26:S3336.

    • Search Google Scholar
    • Export Citation
  • 36

    CupissolDRSerrouBCaubelM. The efficacy of granisetron as prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer1990;26:S2327.

    • Search Google Scholar
    • Export Citation
  • 37

    DeMulderPHMSeynaeveCVermorkenJB. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med1990;113:834840.

    • Search Google Scholar
    • Export Citation
  • 38

    MartyM. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer1990;26(Suppl 1):S2832.

    • Search Google Scholar
    • Export Citation
  • 39

    MartyMPouillartPSchoolS. Comparison of the 5-hydroxytryptamine3 (serotonin) receptor antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med1990;322:816821.

    • Search Google Scholar
    • Export Citation
  • 40

    SoukopM. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer1990;26(Suppl 1):S1519.

    • Search Google Scholar
    • Export Citation
  • 41

    RoilaFTonatoMCognettiF. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol1991;9:675678.

    • Search Google Scholar
    • Export Citation
  • 42

    FraschiniG. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy. Semin Oncol1992;19(4 Suppl 10):S4147.

    • Search Google Scholar
    • Export Citation
  • 43

    KamanabrouD. Intravenous granisetron establishing the optimal dose. Eur J Cancer1992;28A(Suppl 1):S611.

  • 44

    SledgeGWJrEinhornLNagyC. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer1992;70:25242528.

    • Search Google Scholar
    • Export Citation
  • 45

    ChevallierB. The control of acute cisplatin-induced emesis—a comparative study of granisetron and combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer1993;68:176180.

    • Search Google Scholar
    • Export Citation
  • 46

    NavariRMKaplanHGGrallaRJ. Efficacy and safety of granisetron, a selective 5-HT antagonist, in the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol1994;12:22042210.

    • Search Google Scholar
    • Export Citation
  • 47

    RiviereA. Dose-finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer1994;69:967971.

  • 48

    EisenbergPFigueroa-VadilloJZamoraR. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer2003;98:24732482.

    • Search Google Scholar
    • Export Citation
  • 49

    AaproMS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag2007;3:10091020.

  • 50

    GrunbergSGabrialNClarkG. Phase III trial of transdermal granisetron patch (Sancuso) compared to oral granisetron (OG) for chemotherapy-induced nausea and vomiting (CINV) after multi-day moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapy [Abstract]. MASCC/ISOO 20th Anniversary International Symposium Supportive Care in Cancer; St. Gallen, Switzerland; June 27–30, 2007:687. Astract P-18.

    • Search Google Scholar
    • Export Citation
  • 51

    GrallaRLichinitserMVan Der VegtS. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol2003;14:15701577.

    • Search Google Scholar
    • Export Citation
  • 52

    BonneterreJHecquetB. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A crossover study. Bull Cancer1995;82:10381043.

    • Search Google Scholar
    • Export Citation
  • 53

    JantunenITKatajaVVJohanssonRT. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute nausea and vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncol1992;31:573575.

    • Search Google Scholar
    • Export Citation
  • 54

    JantunenITMuhonenTTKatajaVV. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study. Eur J Cancer1993;29A:16691672.

    • Search Google Scholar
    • Export Citation
  • 55

    MartoniSAngelelliBGuaraldiM. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatinum-induced emesis: an open randomized cross-over study. Am Soc Lin Oncol1993;13:431.

    • Search Google Scholar
    • Export Citation
  • 56

    CamporaLESimoniCRossoR. [Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma]. Minerva Med1994;85:2531[in Italian].

    • Search Google Scholar
    • Export Citation
  • 57

    GebbiaVCannataGTestaA. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer1994;74:19451952.

    • Search Google Scholar
    • Export Citation
  • 58

    MantovaniAMaccioLCurreliL. Comparison of the effectiveness of three 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer. Proc Am Soc Clin Oncol1994;13:428.

    • Search Google Scholar
    • Export Citation
  • 59

    MassiddaBLaconiSFoddiMR. Prevention of non-cisplatin induced emesis: role of the antagonists of 5-HT receptors. Ann Oncol1994;5:S204.

  • 60

    NobleABremerKGoedhalsL. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer1994;30:10831088.

    • Search Google Scholar
    • Export Citation
  • 61

    RuffPPaskaWGoedhalsL. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology1994;51:113118.

    • Search Google Scholar
    • Export Citation
  • 62

    Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol1995;6:805810.

    • Search Google Scholar
    • Export Citation
  • 63

    MartyMKleisbauerJPFournelP. Is navoban (tropisetron) as effective as zofran (ondansetron) in cisplatin-induced emesis?Anti-Cancer Drugs1995;6(Suppl 1):S1521.

    • Search Google Scholar
    • Export Citation
  • 64

    NavariRGandaraDHeskethP. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol1995;13:12421248.

    • Search Google Scholar
    • Export Citation
  • 65

    StewartAMcQuadeBCronjeJDE. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in outpatients: a multi-centre, double-blind, double dummy, randomised, parallel-group study. Oncology1995;52:202210.

    • Search Google Scholar
    • Export Citation
  • 66

    AudhuyBCappelaerePMartinM. A double-blind, randomised comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer1996;32A:807813.

    • Search Google Scholar
    • Export Citation
  • 67

    FauserAADuclosBChemaissaniA. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondaneston for the prevention of amesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer1996;32A:15231529.

    • Search Google Scholar
    • Export Citation
  • 68

    HeskethPJNavariRGroteT. Double-blind, randomised comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol1996;14:22422249.

    • Search Google Scholar
    • Export Citation
  • 69

    LeonardiVIannittoEMeliMPalmeriS. Ondansetron vs granisetron in the control of chemotherapy-induced acute emesis: a multicenter randomized trial. Oncology Rep1996;3:919923.

    • Search Google Scholar
    • Export Citation
  • 70

    LoftersWSPaterJLZeeB. Phase III double-blind comparison of dolasetron mesylate and ondansetron, and evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol1997;15:29662973.

    • Search Google Scholar
    • Export Citation
  • 71

    JordanKHinkeAGrotheyA. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer2007;15:10231033.

    • Search Google Scholar
    • Export Citation
  • 72

    HuangJQZhengGFDeusonR. Do 5-hydroxytryptamine3 receptor antagonists (5-HT3) improve the antiemetic effect of dexamethasone for preventing delayed chemotherapy-induced nausea and vomiting (CINV)? A meta-analysis of randomized controlled trials [Abstract]. J Clin Oncol2004;22:Abstract 6037.

    • Search Google Scholar
    • Export Citation
  • 73

    ChawlaSPGrunbergSMGrallaRJ. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer2003;97:22902300.

    • Search Google Scholar
    • Export Citation
  • 74

    HeskethPJGrunbergSMGrallaRJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol2003;21:41124119.

    • Search Google Scholar
    • Export Citation
  • 75

    de WitRHerrstedtJRapoportB. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer2004;40:403410.

    • Search Google Scholar
    • Export Citation
  • 76

    WarrDGEisenbergPHeskethPJ. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: a randomized double-blind trial in 866 patients [Abstract]. J Clin Oncol2004;22:Abstract 8007.

    • Search Google Scholar
    • Export Citation
  • 77

    WarrDGHeskethPJGrallaRJ. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol2005;23:28222830.

    • Search Google Scholar
    • Export Citation
  • 78

    GrallaRJWarrDGCaridesAD. Effect of aprepitant on antiemetic protection in patients receiving moderately emetogenic chemotherapy plus high-dose cisplatin: analysis of combined data from 2 phase III randomized clinical trials [abstract]. J Clin Oncol2004;22:Abstract 8137.

    • Search Google Scholar
    • Export Citation
  • 79

    Tremont-LukatsIWGonzález-BarboteoJBrueraE. Meta-analysis of neurokinin-1 receptor antagonists (NK-1 RA) for chemotherapy-induced nausea and vomiting (CINV) [Abstract]. J Clin Oncol2004;22:Abstract 8047.

    • Search Google Scholar
    • Export Citation
  • 80

    GroteTHajdenbergJCartmellA. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol2006;4:403408.

    • Search Google Scholar
    • Export Citation
  • 81

    ShadleCRLeeYMajumdarAK. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol2004;44:215223.

    • Search Google Scholar
    • Export Citation
  • 82

    Emend [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2003. Available at: http://www.fda.gov/cder/foi/label/2008/021549s015lbl.pdf. Accessed April 7 2009.

    • Search Google Scholar
    • Export Citation
  • 83

    WamplerG. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs1983;25:3151.

    • Search Google Scholar
    • Export Citation
  • 84

    GrallaRJBraunTJItriLM. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med1981;305:905909.

    • Search Google Scholar
    • Export Citation
  • 85

    GrallaRJTysonLBBordenLA. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep1984;68:163172.

    • Search Google Scholar
    • Export Citation
  • 86

    BakowskiMT. Advances in anti-emetic therapy. Cancer Treat Rev1984;11:237256.

  • 87

    GrossmanBLessenLSCohenP. Droperidol prevents nausea and vomiting from cisplatinum (letter). N Engl J Med1979;301:7.

  • 88

    AaproMSAlbertsDS. High dose dexamethasone for prevention of cisplatinum-induced vomiting. Cancer Chemother Pharmacol1981;7:1114.

  • 89

    AaproMSPleziaPMAlbertsDS. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol1984;2:466471.

    • Search Google Scholar
    • Export Citation
  • 90

    CassilethPALuskEJTorriS. Antiemetic efficacy of dexamethasone therapy in patients receiving chemotherapy. Arch Intern Med1983;143:13471349.

    • Search Google Scholar
    • Export Citation
  • 91

    KrisMGGrallaRJClarkRA. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep1985;69:12571262.

    • Search Google Scholar
    • Export Citation
  • 92

    KrisMGGrallaRJClarkRA. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide plus dexamethasone: a double-blind, randomized trial. Cancer1987;69:13531357.

    • Search Google Scholar
    • Export Citation
  • 93

    HermanTSEinhornLHJonesSE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med1979;200:12951297.

    • Search Google Scholar
    • Export Citation
  • 94

    SteeleNGrallaRJBraunDW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep1980;64:219224.

    • Search Google Scholar
    • Export Citation
  • 95

    NavariRMEinhornLHLoehrerPJ. A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV) [Abstract]. J Clin Oncol2004;22:Abstract 8046.

    • Search Google Scholar
    • Export Citation
  • 96

    NavariRMEinhornLHPassikSD. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer2005;13:529534.

    • Search Google Scholar
    • Export Citation
  • 97

    SrivastavaMBrito-DellanNDavisMP. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage2003;25:578582.

    • Search Google Scholar
    • Export Citation
  • 98

    PassikSDNavariRMJungSH. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest2004;22:383388.

    • Search Google Scholar
    • Export Citation
  • 99

    PassikSDKirshKLTheobaldDE. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage2003;25:485488.

    • Search Google Scholar
    • Export Citation
  • 100

    PassikSDLundbergJKirshKL. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage2002;23:526532.

    • Search Google Scholar
    • Export Citation
  • 101

    MoritaTTeiYShishidoH. Olanzapine-induced delirium in a terminally ill cancer patient. J Pain Symptom Manage2004;28:102103.

  • 102

    SaitoMAogiKSekineI. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol2009;10:115124.

    • Search Google Scholar
    • Export Citation
  • 103

    GelingOEichlerH-G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol2005;23:12891294.

    • Search Google Scholar
    • Export Citation
  • 104

    MassaEAstaraGMadedduC. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit Rev Oncol Hematol2009;70:8391.

    • Search Google Scholar
    • Export Citation
  • 105

    FranzenLNymanJHagbergH. A randomized placebo-controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol1996;7:587592.

    • Search Google Scholar
    • Export Citation
  • 106

    WongRKPaulNDingK. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol2006;24:34583464.

    • Search Google Scholar
    • Export Citation
  • 107

    BelkacemiYOzsahimMPeneF. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiation Oncol Biol Phys1996;36:7782.

    • Search Google Scholar
    • Export Citation
  • 108

    OkamotoSTakahashiSTanosakiR. Granisetron in the prevention of vomiting induced conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant1996;17:679683.

    • Search Google Scholar
    • Export Citation
  • 109

    EzzoJVickersARichardsonMA. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol2005;23:71887198.

    • Search Google Scholar
    • Export Citation
  • 110

    MorrowGRMorrellC. Behavioral treatment for the anticipating nausea and vomiting induced by cancer chemotherapy. N Engl J Med1982;307:14761480.

    • Search Google Scholar
    • Export Citation
  • 111

    ReddWHAndrykowskiMA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. J Consult Clin Psychol1982;50:10181029.

    • Search Google Scholar
    • Export Citation
  • 112

    RazaviDDelvauxNFarvacquesC. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study of assessing the usefulness of alprazolam. J Clin Oncol1993;11:13841390.

    • Search Google Scholar
    • Export Citation
  • 113

    Physicians’ Desk Reference58th ed. Montvale, NJ: Thomson PDR; 2004. Available at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5816#nlm34068-7. Accessed April 7 2009.

    • Search Google Scholar
    • Export Citation
  • 114

    EllebaekEHerrstedtJ. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care2008;2:2834.

    • Search Google Scholar
    • Export Citation
  • 115

    EinhornLHRapoportBKoellerJ. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer2005;13:112116.

    • Search Google Scholar
    • Export Citation
  • 116

    NavariRM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw2007;5:5159.

  • 117

    HerrstedtJSigsgaardTCNielsenHA. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer2007;15:417426.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 119 119 14
PDF Downloads 19 19 6
EPUB Downloads 0 0 0